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RAS signaling is central to many cellular processes and SOS proteins promote RAS 
activation. To investigate the role of SOS proteins in T cell biology, we crossed Sos1f/f 
Sos2−/− mice to CD4-Cre transgenic mice. We previously reported an effect of these 
mutations on T cell signaling and T cell migration. Unexpectedly, we observed nodules 
on the joints of greater than 90% of these mutant mice at 5 months of age, especially 
on the carpal joints. As the mice aged further, some also displayed joint stiffness, hind 
limb paralysis, and lameness. Histological analysis indicated that the abnormal growth 
in joints originated from dysplastic chondrocytes. Second harmonic generation imag-
ing of the carpal nodules revealed that nodules were encased by rich collagen fibrous 
networks. Nodules formed in mice also deficient in RAG2, indicating that conventional 
T cells, which undergo rearrangement of the T cell antigen receptor, are not required for 
this phenotype. CD4-Cre expression in a subset of cells, either immune lineage cells 
(e.g., non-conventional T cells) or non-immune lineage cells (e.g., chondrocytes) likely 
mediates the dramatic phenotype observed in this study. Disruptions of genes in the RAS 
signaling pathway are especially likely to cause this phenotype. These results also serve 
as a cautionary tale to those intending to use CD4-Cre transgenic mice to specifically 
delete genes in conventional T cells.
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inTrODUcTiOn
The RAS/MAP kinase signaling pathway is central for cellular activation through numerous cell 
surface receptors. Furthermore, RAS is mutated in approximately 30% of all human tumors, making 
its study relevant to normal and cancer cell biology (1, 2). RAS can cycle between GTP- and GDP-
bound forms and RAS guanine exchange factors (GEFs) facilitate conversion to the GTP-bound/
active form of RAS. SOS1 is a prototypical RAS GEF. In T cells, activation through the T cell antigen 
receptor (TCR) results in RAS activation via SOS1 and other GEFs. RAS mediates downstream 
activation of the MAP kinases ERK1 and ERK2 (3, 4). Four RAS GEFs are active in developing and 
mature T cells: SOS1, SOS2, RASGRP1, and RASGRP4. Their relative expression levels determine 
their contributions to thymocyte development and T cell activation (3).
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Genetic analysis has been essential for investigating the 
roles of SOS proteins in T  cells. Investigation of SOS1 func-
tion was impeded when SOS1 deficiency in mice was found 
to be embryonic lethal (5). Kortum et  al. generated floxed 
(conditional) Sos1-deficient mice to address the function of 
SOS1 in specific cell lineages (6). By crossing Sos1f/f mice to 
Lck-Cre transgenic mice, SOS1 deficiency was achieved in 
developing and mature T cells. T cell development was partially 
disrupted. The effect on T cell development was mediated by 
both scaffolding and GEF functions of SOS1 (7). To bypass the 
effects of SOS1 on T cell development and to study the effects 
of SOS1 deficiency on mature T cells, we crossed Sos1f/f mice 
with CD4-Cre transgenic mice (8). In addition, those mice 
were bred to mice deficient for the related Sos family member 
SOS2 (9). Sos1f/f Sos2−/− CD4-Cre+ mice had normal numbers 
and subsets of T  cells. T  cells from Sos1f/f Sos2−/− CD4-Cre+ 
mice had intact ERK activation downstream from the TCR but 
defective ERK activation downstream from the IL-2 receptor. 
The Sos1f/f Sos2−/− CD4-Cre+ mice displayed defects in T  cell 
migration that were secondary to increased PI3kinase activity 
in T cells (8).
For the latter studies, CD4-Cre was chosen for conditional 
knockout of Sos1 because it is expressed later in thymocyte 
development than Lck-Cre (10). Lck-Cre is expressed at the early 
CD4 CD8 double negative stage whereas CD4-Cre is expressed 
at the transitional CD4 CD8 double positive stage. CD4-Cre is 
widely used for conditional deletion of genes in double positive 
and mature T cells as the original description of CD4-Cre (11) has 
been cited over 500 times. Recently the integration of the CD4-
Cre transgene, which expresses the Cre recombinase gene under 
the control of the promoter and regulatory elements of the Cd4 
gene, has been mapped to mouse chromosome 3 and is present 
in at least 15 copies (12).
In addition to the signaling effects described above that 
we observed in mature T cells from Sos1f/f Sos2−/− CD4-Cre+ 
mice, we also observed that the mice developed nodules on 
multiple joints as they aged, especially carpal joints, and could 
eventually develop hind limb paralysis and become lame. We 
postulate that these disabling defects arise from abnormal 
cartilage homeostasis. Our unexpected results of a cartilage-
based phenotype in Sos1f/f Sos2−/− CD4-Cre+ mice provide 
evidence that CD4-Cre expression may not be restricted to 
conventional double positive and mature CD4+ and CD8+ 
T cells.
MaTerials anD MeThODs
Mice
Sos1f/f and Sos2−/− mice were previously described (6, 9). CD4-
Cre transgenic mice were from Taconic (Hudson, NY, USA). 
Rag2-deficient mice were from Jackson Laboratory (Bar Harbor, 
ME, USA). All mice were on a C57BL/6 background. Mice were 
housed at the National Cancer Institute (NCI). This study was 
carried out in accordance with guidelines set forth by the NCI-
Bethesda Animal Care and Use Committee. The protocol was 
approved by the NCI-Bethesda Animal Care and Use Committee.
clinical scoring
Mice were scored using the parameters listed in Figure 1E legend 
by an observer who was blind to the genotypes of the mice. Mice 
with high clinical scores were fed with gelmeal inside the cage in 
cases where it was suspected that the mice might have difficulty 
reaching food.
computerized Tomographic (cT) imaging
Mice were euthanized and fixed in neutral buffered formalin for 
24 h. Then, mice were preserved in 70% ethanol prior to imaging. 
3D images were acquired on a CT animal scanner with a resolu-
tion of 9 µm. CT imaging was performed by the Mouse Imaging 
Facility of the NIH In Vivo NMR Center.
histology
Sections of bone were decalcified, embedded in paraffin, sectioned 
at 5 µm, and stained with H&E and Toluidine blue using standard 
techniques by the Pathology/Histotechnology Laboratory of the 
Laboratory Animal Sciences Program at NCI-Frederick. Stained 
slides were scanned into a digital format an Aperio Scanscope 
XT (Leica, Vista, CA, USA) at 20× magnification. Images were 
captured using Aperio ImageScope v12.2.2.5015.
second harmonic generation (shg) 
imaging
The carpal nodules and control areas were excised from the mice, 
placed on a coverglass, and imaged by SHG, using an inverted 
laser scanning two-photon microscope (MPE-RS, Olympus, 
Center Valley, PA, USA) equipped with a tunable laser (Insight 
DS+, Spectra Physics, Santa Clara, CA, USA). Samples were 
excited at 900 nm and the SHG signal (450 nm) was collected 
on a GaAs detector using a dichroic mirror (SDM570) and a 
bandpass filter (BP/410-470). Low magnification images were 
acquired using a 4× air objective [UPLSAPO4X(F), Olympus] 
whereas high magnification images were acquired with a silicon 
oil immersion 30× objective (UPLSAPO30XIR, Olympus).
Purification of cD4+ T cells/Dna isolation/
genomic Pcr
CD4+ T  cells were isolated from lymph nodes and spleens of 
Sos1f/f Sos2−/− CD4-Cre+ mice using EasySep Mouse CD4+ T Cell 
Isolation Kit (Stem Cell Technologies, Cambridge, MA, USA). 
Purity was >80%. Non-lymphoid tissues were homogenized 
prior to DNA isolation using a TissueMiser System, 115 V (Fisher 
Scientific, Hampton, NH, USA). Tissue DNA was isolated using 
DNA columns from a ZR-Duet DNA/RNA MiniPrep Plus kit 
(Zymo Research, Irvine, CA, USA). Genotyping PCRs used for 
tissue DNAs were described previously (6).
rna isolation from growth Plate
Proximal tibias were dissected from 1-week-old wild-type 
C57BL/6 male mice and, from them, the growth plate cartilage 
in the center was isolated by removing the metaphyseal bone, 
perichondrium, meniscus, and articular cartilage. The growth 
plate cartilage was homogenized and RNA isolated using an 
RNeasy mini kit following the manufacturer’s instructions 
FigUre 1 | Joint abnormalities in sos1/2 dKO mice. (a) Nodules are evident on the carpal joints of a 45-week-old Sos1/2 dKO mouse (left, arrows) and not on 
a 45-week-old Sos2 KO mouse (right). (B–D) Computerized tomographic (CT) images of 32-week-old Sos1/2 dKO mouse. Videos S1 and S2 in Supplementary 
Material contain 3D video images of Sos1/2 dKO and control Sos2 KO CT scanning. (e) The four genotypes under study are listed with their color codes. A clinical 
score was determined for individual mice at 20 and 26 weeks of age. The clinical scores were based on the presence of nodules on joints, joint flexibility, and gait.  
A score of 1 indicates no nodules on joints, normal joint flexibility, and normal gait. A score of 2 indicates nodules visible on joints upon close inspection, normal joint 
flexibility, and normal gait. A score of 3 indicates clearly visible nodules on joints, normal joint flexibility, and slightly abnormal gait. A score of 4 indicates nodules 
visible cageside on multiple joints, reduced joint flexibility, and abnormal gait visible cageside. A score of 5 indicates nodules visible cageside on multiple joints, 
severely reduced joint flexibility, and reduced movement in a foreign area (severely lame). A score of 6 indicates nodules visible cageside on multiple joints, severely 
reduced joint flexibility with no flexibility in hind limbs, and no movement in a foreign area (extremely lame). For WT, n = 8 at 20 weeks and 7 at 26 weeks; for Sos1 
KO, n = 13; for Sos2 KO, n = 13 at 20 weeks and 11 at 26 weeks; for Sos1/2 dKO, n = 19 at 20 weeks and 18 at 26 weeks.
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(Qiagen). RNA integrity was determined using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and 
only high quality RNA (RIN > 7) was used for real-time RT-PCR.
Quantitative real-time rT-Pcr
Real-time PCR was used to compare gene expression in CD4+ 
T cells purified as described above from C57BL/6 lymph nodes in 
single cell suspensions from C57BL/6 lymph nodes and in growth 
plate chondrocytes. Total RNA (500 ng) was reverse-transcribed 
using SuperScript IV Reverse Transcriptase (Thermo Scientific). 
Quantitative real-time PCR was performed for 18S, Sos1, Cd4, 
Cd3e, and Col2a1 using commercially available FAM or VIC-
labeled Taqman assays (Thermo Scientific). All assays or primer 
pairs were intron-spanning to avoid amplification of genomic 
DNA. Reactions were performed in triplicate using the ViiA 7 
Real-time PCR System (Thermo Scientific). The relative quantity 
of each mRNA was calculated using the formula: relative expres-
sion = 2−ΔCt × 108, where Ct represents the threshold cycle and 
ΔCt = (Ct of gene of interest) − (Ct of 18S rRNA). Values were 
multiplied by 108 for convenience of comparison.
resUlTs
To investigate the effects of Sos1 and Sos2 deletion in T  cells, 
we crossed Sos1f/f Sos2−/− mice to CD4-Cre transgenic mice. 
Expression of Cre recombinase in CD4 CD8 double positive 
thymocytes, in single positive thymocytes, and in mature CD4+ 
and CD8+ T cells results in an absence of SOS protein expression 
in these cells, which is consequent to the deletion of Sos1 exon 10 
by Cre recombinase (6). We were surprised, then, to observe that 
Sos1f/f Sos2−/− CD4-Cre+ mice developed visible nodules on mul-
tiple joints, especially carpal joints (Figure 1A, arrows) and had 
reduced joint flexibility by about 16 weeks of age. 3D CT imaging 
of a 32-week-old Sos1f/f Sos2−/− CD4-Cre+ mouse showed bony 
protrusions on the carpal joints and severe kyphosis of the spine 
(Figures 1B–D; Videos S1 and S2 in Supplementary Material). 
As the mice aged, some exhibited hind limb paralysis and became 
lame. Figure 1E shows clinical scoring based on nodule presence 
on joints, joint flexibility, and gait. An observer blinded to the 
genotypes scored the mice at 20 and 26 weeks of age. The observer 
examined the following four genotypes: WT (Sos1f/f Sos2+/+ 
CD4Cre−), Sos1 KO (Sos1f/f Sos2+/+ CD4Cre+), Sos2 KO (Sos1f/f 
Sos2−/− CD4Cre−), and Sos1/2 dKO (Sos1f/f Sos2−/− CD4Cre+). 
With the exception of one Sos2 KO mouse, the only mice that 
scored above a normal clinical score of 1 were Sos1/2 dKO mice. 
At 26 weeks of age, 16 of 17 Sos1/2 dKO mice had measurable 
clinical manifestations of disease and 12 of 17 Sos1/2 dKO mice 
had severely reduced joint flexibility and were lame (clinical score 
greater than or equal to 4).
To further characterize the abnormal structures that we 
observed clinically, we performed histological analysis on the 
vertebrae, carpal joints, and stifle joints of Sos1/2 dKO and 
control Sos2 KO mice. Figure 2 shows Hematoxylin and Eosin 
staining and Toluidine blue staining of vertebrae and carpal 
joints. Toluidine blue staining, which preferentially stains car-
tilage blue, showed increased amounts of abnormally organized 
cartilage in these joints in Sos1/2 dKO mice, but not Sos2 KO 
mice. By 12  weeks of age, the growth plates of Sos1/2 dKO 
mice showed proliferation of dysplastic chondrocytes and these 
changes became more prominent over time. By 25 and 39 weeks, 
dysplastic chondrocyte proliferation had resulted in irregular 
and sometimes severe thickening of the physes that multifocally 
impinged on adjacent structures, including the spinal cord. Spinal 
cord compression likely contributed to the hind limb paresis and 
altered gait seen clinically in these mice. Importantly, there was 
no evidence of lymphocyte infiltration or inflammation in Sos1/2 
dKO sections.
To better understand the tissue architecture of the carpal 
nodules, we performed SHG imaging of Sos1/2 dKO carpal 
nodules and the corresponding area of control Sos2 KO carpal 
joints. SHG enables the label-free visualization of collagen fibers 
in various tissues, as previously shown (13). A loosely organized 
pattern of wavy collage fibrils was observed in control carpal 
joints (Figures 3A,C). In contrast, the pattern in the Sos1/2 dKO 
carpal nodules contained relatively straight collagen fibrils that 
were closely aligned (Figures 3B,D). SHG imaging of edges of the 
nodules indicated that the nodules seemed to be encased in a rich 
collagen network (Figure 3E).
Because T  cell infiltration was not seen histologically in 
carpal nodule sections (Figure  2C), we postulated that some 
other non-T cells in the Sos1/2 dKO nodules might have deleted 
Sos1 exon 10. To investigate Sos1 deletion in carpal nodules, we 
homogenized nodule tissue and performed a genomic PCR that 
distinguishes between wild-type Sos1, floxed Sos1, and deleted 
Sos1 (Figure  4). Lanes 5 and 7 show that nodule tissue does 
indeed contain cells with Sos1 exon 10 deletion. We also spiked 
normal tissue with known numbers of mature, deleted CD4+ 
T cells derived from the lymphoid organs of Sos1/2 dKO mice. 
These samples showed that greater than 104  T  cells/mg tissue 
would be required to see a deleted signal such as that seen in 
lanes 5 and 7. Examination of the pathology of Sos1/2 dKO carpal 
tissue indicates that it is extremely unlikely that the deleted PCR 
band originating from carpal tissue arises exclusively from T cells 
because lymphocyte infiltration was not observed in nodule 
sections.
To investigate whether normal chondrocytes express Cd4 and, 
therefore, might be susceptible to CD4-Cre-mediated deletion, 
we performed quantitative real-time RT-PCR on growth plate 
cartilage from 1-week-old wild-type mice (Table  1). Levels of 
Cd4 expression were extremely low compared to the positive 
controls from lymph node single cell suspensions and purified 
CD4+ lymph node T cells. However, the levels of Cd4 expression 
in growth plate cartilage were slightly higher than Cd3e levels.
To more definitively determine if mature, conventional 
CD4+ and CD8+ T cells, which are the usual intended target of 
CD4-Cre transgenesis, were responsible for cartilage disease and 
nodule formation in Sos1/2 dKO mice, we crossed Sos1/2 dKO 
mice to mice deficient in RAG2, a recombinase that is required 
for the formation of mature T and B lymphocytes. As shown in 
Table 2, all Sos1/2 dKO Rag2−/− mice developed carpal nodules 
at 18–20 weeks similar to Sos1/2 dKO Rag2+/+ mice. At 26 weeks, 
6 of 6 Sos1/2 dKO Rag2−/− mice had a maximum clinical score of 
6 whereas 2 of 4 Sos1/2 dKO Rag2+/+ mice had a clinical score of 
6. These data indicate that mature, conventional TCR-expressing 
FigUre 2 | chondrocyte dysplasia in sos1/2 dKO joints. (a) At low magnification, control Sos2KO (left) versus Sos1/2 dKO (right) showed clear differences 
following toluidine blue staining. The radial physis of Sos1/2 dKO animals is expanded by chondrocytes and the medullary cavity is enlarged significantly 
(scalebar = 3 mm). (B) Vertebrae (top panels, 4× magnification, scalebar = 600 µm) and carpal joints (bottom panels, 5× magnification, scalebar = 500 µm) were 
sampled at various times and stained with toluidine blue to compare the changes in affected joints over time. (c) H&E staining of vertebrae (top) and carpal joints 
(bottom) as in (B). Control Sos2 KO mice had normal vertebrae and carpal joints at all time points. Beginning at 12 weeks of age, proliferation of dysplastic 
chondrocytes was seen at growth plates of Sos1/2 dKO mice, and these changes became more pronounced over time. There was prominent, irregular thickening 
of the physes (hollow arrows) and multifocal areas of unresorbed cartilage in the metaphyses (thin arrows). The proliferations of dysplastic chondrocytes, both within 
the growth plate and protruding from it, impinged on adjacent structures including the spinal cord (thick arrows), likely contributing to the secondary clinical signs 
seen in these animals including hind limb paresis and altered gait.
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T cells are not required for development of the cartilage-based 
disease described in this study. In fact, in the absence of con-
ventional T and B lymphocytes, clinical disease was more severe.
DiscUssiOn
To investigate the role of SOS proteins in T  cells, we crossed 
Sos1f/f Sos2−/− mice with CD4-Cre transgenic mice. We previously 
reported no effect on T cell numbers, but an effect of these muta-
tions on T cell signaling and T cell migration (8). Unexpectedly, 
as the dKO mice aged, we observed nodules in the joints of 
greater than 90% of these mutant mice, especially at carpal 
joints. Histological analysis suggested that the abnormal growth 
originated from dysplastic chondrocytes. An important question 
is whether the joint abnormality that we observed is caused by 
T cells, as would be expected from using CD4-Cre, or by other 
non-T  cells expressing CD4-Cre sometime in their lifetime. 
Histological analysis did not show lymphocytic infiltrates in the 
nodules. Furthermore, crosses to Rag2−/− mice indicated that the 
phenotype was not caused by T cells, at least not conventional 
T cells that undergo rearrangement of the TCR, because nodules 
still formed in the joints of the Sos1/2 dKO Rag2−/− mice.
What is the origin of the chondrocyte dysplasia in Sos1/2 
dKO mice? One possible scenario is that the cartilage nodules 
arise from impaired SOS/RAS/MAPK signaling in a rare 
subset of chondrocytes consequent to CD4-Cre expression 
in those chondrocytes. Analysis of Cd4 RNA expression in 
normal chondrocytes from growth plate cartilage showed low, 
but detectable, expression leaving open the possibility that 
CD4-Cre is active in a small subset of chondrocytes. This 
scenario is consistent with previous studies demonstrating 
that the RAS signaling pathway, mediated by SOS, inhibits 
chondrocyte proliferation (14). In chondrocytes, a fibroblast 
growth factor, FGFR3, signals through SOS to activate the 
RAS/MAPK pathway. Downstream from RAS, RAF activates 
MEK1/2 and MEK5/6, which activate ERK and p38, respec-
tively. Postnatal chondrocyte-specific Fgfr3 deletion results in 
chondroma-like lesions (15). Other RAS/MAPK perturbations 
that result in bone growth abnormalities include constitutively 
active MEK1 (16) and conditional inactivation of Erk1 and 
Erk2 in chondrocytes (17). Similarly, conditional knockout 
of Shp2 in chondrocytes results in the formation of cartilagi-
nous nodules, similar to the phenotype seen in the current 
study. SHP2 is a protein tyrosine phosphatase that mediates 
FigUre 3 | second harmonic generation of collagen network surrounding carpal joints. Tissue surrounding carpal joints was excited at 900 nm and 
backscattered emissions collected at 410–470 nm to reveal the SHG signal. (a) Sos2 KO (32 weeks), (B) Sos1/2 dKO (32 weeks), (c) WT (48 weeks), (D) Sos1/2 
dKO (48 weeks). Scale bar = 50 μm. (e) Intensity Z-stack of a carpal joint nodule for the mouse used in panel (D). Scale bar = 40 μm.
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RAS/MAPK signaling downstream from many growth factor 
receptors including FGFR (18, 19).
In humans, patients with Noonan syndrome have inherited 
mutations in RAS/MAPK pathway genes. Noonan syndrome is a 
multisystem and varied disease often characterized by distinctive 
facial features, developmental delay, short stature, congenital 
heart disease, and other abnormalities (20). About 10% of Noonan 
syndrome patients have SOS1 mutations that are thought to 
confer hyperactivity of SOS1. The short stature in these patients 
suggests that activating mutations in SOS1 impair growth plate 
chondrogenesis, whereas in our mouse model, loss of SOS1 and 
SOS2 appears to increase chondrogenesis.
TaBle 2 | sos1/2 dKO clinical disease is not dependent on conventional 
T cells.
genotype number of mice with 
clinical score >1 at 
18–20 weeks of agea
number of mice with 
clinical score = 6 at 
26 weeks of agea
Rag2+/+ Sos1/2 dKO 3/4 2/4
Rag2−/− Sos1/2 dKO 5/5 6/6
aClinical scores were determined by an observer blinded to genotype. The clinical 
scoring method is described in the legend of Figure 1.
TaBle 1 | relative expressiona of Cd4 in wild-type growth plate cartilage.
Tissue Cd3e Cd4 Sos1 Col2a1
Lymph node 67,775 8,388 1,961 0
CD4+ T cells 166,058 37,825 3,084 0
Growth plate 1 4 19 431 388,222
Growth plate 2 5 40 623 430,022
aRelative expression levels were determined by quantitative real-time RT-PCR as 
described in Section “Materials and Methods.” Growth plates 1 and 2 are biological 
replicates.
FigUre 4 | Sos1 exon 10 excision in tissues from sos1/2 dKO mice.  
A 3 primer PCR was performed to yield wild-type Sos1 bands (bottom bands), 
floxed Sos1 (middle bands), and deleted Sos1 (upper bands, arrow). Lanes: 
1–11 as indicated in figure, (12) Sos1+/+ control, (13) Sos1+/f control, (14) Sos1f/f 
control, (15) Sos1f/f + Cre control. For lanes 1 and 2, a 35-week-old C57BL/6 
mouse was used. For lanes 3 and 4, a 34-week-old, for lanes 5 and 6, a 
36-week-old, and for lanes 7 and 8, a 22-week-old Sos1/2 dKO was used.
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Although it is possible that some rare chondrocytes express 
Cd4 and that chondrocyte dysplasia results from SOS deficiency 
in those chondrocytes, it is also possible that conventional T cells 
regulate chondrocyte proliferation and that SOS deficiency in 
T cells results in alterations in secretion of factors that normally 
keep chondrocyte proliferation in check. This cannot be the 
only mechanism at play, however, because Rag2−/− mice (with 
wild-type SOS) do not have conventional T  cells and do not 
exhibit a cartilage phenotype. Another possible scenario is 
that immune regulatory cells, which express Cd4 sometime in 
their lifetime, but are not conventional T or B lymphocytes, 
keep chondrocyte proliferation in check. Consequent to SOS 
deficiency in these cells, chondrocyte dysplasia would result, 
disturbing cartilage homeostasis. Our results that 26-week-old 
Sos1/2 dKO Rag2−/− mice have more severe disease than Sos1/2 
dKO Rag2+/+ mice could indicate that imbalances in immune 
cell subpopulations can alter cartilage homeostasis. At the least, 
these results imply that the disease is not completely due to a 
chondrocyte effect. Some combination of these possible causes 
of chondrocyte dysplasia, SOS deficiency in rare chondrocyte 
populations, in T  cells, or in regulatory non-T  cells, may be 
responsible for development of this clinical disease. Control of 
cartilage homeostasis by T cells and/or by hypothetical immune, 
non-T cells would reveal a novel function for the immune system.
The extensive prior evidence that SOS/RAS/MAPK pathway 
signaling inhibits chondrogenesis provides for the possibility 
that Sos1 is excised by CD4-Cre in occasional chondrocytes or 
chondrocyte precursors. In combination with the germline loss of 
Sos2, RAS/MAPK signaling could be impaired, stimulating chon-
drocyte proliferation and nodule formation. Alternatively, Sos1 
could be deleted in other cell types that regulate chondrogenesis 
via the secretion of cytokines or growth factors. In accordance 
with the hypothesis that CD4-Cre-regulated deletion of SOS/
RAS/MAPK pathway genes can lead to the cartilage-based 
phenotype described here, the laboratory of Maureen McGargill 
has found that mice with both a germline mutation of Erk1 and 
conditional deletion of Erk2 mediated by CD4-Cre exhibit a 
similar disease to that described in this study (Marie Wehenkel 
and Maureen McGargill, St. Jude Children’s Research Hospital, 
Memphis, TN, USA, personal communication). As ERK kinases 
are MAPKs activated downstream from SOS proteins, it is 
extremely likely that the SOS/RAS/MAPK pathway causes the 
phenotype described here. Our results serve as a cautionary tale 
to those intending to use CD4-Cre transgenic mice. In addition 
to being expressed in conventional T  cells, CD4-Cre may be 
expressed in a subset of non-T cells, either immune lineage cells 
(e.g., non-conventional T cells) or non-immune lineage cells (e.g., 
chondrocytes). This expression may give rise to the dramatic phe-
notype observed here, depending on the gene being deleted by 
the Cre recombinase. Disruptions of genes in the RAS signaling 
pathway are particularly likely to render this phenotype.
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